Use of Large Real-World Datasets to Improve Practice Guidelines and Clinical Study Designs in Metabolic Diseases

Life Sciences, Clinical Trials, Patient Recruitment & Retention,
  • Thursday, September 02, 2021

Over the last decade, the collection and analysis of personal medical data has expanded and has been applied to understand population health parameters, trends and individual preferences. Practically speaking, these data can provide insights to help drive improvements in healthcare delivery. In this webinar, we will highlight the Labcorp clinical data set—a massive resource containing more than 30 billion clinical laboratory test results—and how it might provide such insights and validation. Importantly, we will also discuss how these datasets can provide actionable implementation, in particular how organizations such as AMGA are providing solutions to improve health and healthcare by serving as a catalyst and collaborator within health systems, addressing concerns of population health, resource needs and standards of care.


Dara Schuster, Labcorp Drug Development

Dara Schuster, MD., Senior Medical Director, Global Clinical Development, Labcorp Drug Development

Dr. Dara Schuster is a healthcare executive with extensive clinical, pharmaceutical industry and leadership experience.

As the CEO of T1D Exchange, Inc., a nonprofit type 1 diabetes research organization, Dr. Schuster built and aligned the mission, vision and 5-year strategic plan, managed all operational aspects of the organization, delivered three unique, functioning data platforms and developed external partnerships for type 1 diabetes research and philanthropy.

Prior to this, Dr. Schuster worked at Eli Lilly & Company from 2012-2018, with her last role being Senior Medical Director, Lilly Diabetes USA and Puerto Rico. In this role, she provided leadership in the areas of medical planning for late phase clinical trials and oversight of the research plans across the Lilly Diabetes Portfolio for USA. Dr. Schuster was responsible for oversight of the medical affairs launch teams for the new Lilly Diabetes assets as well support of strategy execution for existing molecules. She also worked in the area of real-world evidence use for patient care innovation.

Dr. Schuster is a graduate of The University of Kentucky School of Medicine. She completed residency in a combined Internal Medicine and Pediatrics Program and fellowship in Adult and Pediatric Endocrinology at The Ohio State University. She was on faculty there from 1996-2012. During her tenure she worked as a clinical endocrinologist, teacher, researcher and hospital administrator. Dr. Schuster currently holds the academic title of Adjunct Professor.

Message Presenter
Barry Goldstein, Covance by Labcorp

Barry J. Goldstein, MD, PhD, Vice President and Therapeutic Area Head, Cardiovascular, Metabolic, Endocrine and Renal, Labcorp Drug Development

Dr. Barry J. Goldstein is a board certified Endocrinologist who is an internationally recognized authority on diabetes mellitus. Dr. Goldstein has over 30 years of broad experience in clinical and basic R&D in academia and industry. He was Vice President and Therapeutic Area Head for Diabetes and Endocrinology at Merck from 2008-2013 and his clinical development experience spans from small molecules, combination therapies, novel insulin analogs, biosimilars, incretin peptides and novel biologics. Dr. Goldstein joined Labcorp Drug Development in 2013 to assume the position he currently holds.

Dr. Goldstein received his combined MD/PhD degrees from the University of Rochester School of Medicine and Dentistry and completed postdoctoral research and clinical fellowships at the Joslin Diabetes Center of Harvard Medical School. In 1992, he joined Jefferson Medical College in Philadelphia, where he spent 16 years as Professor and Division Chief for Endocrinology and Diabetes. Dr. Goldstein expanded basic and clinical research programs at Jefferson, elevated the reputation of the clinical practice to a tertiary referral center and established a robust Phase II-IV clinical trials unit. Dr. Goldstein has served as PI or Co-PI on over 100 clinical trials. He is an elected member of the ASCI and AAP, a past Associate Editor of the two major journals is his specialty, DIABETES and the JCEM, and has served on many grant review and scientific advisory panels. His numerous contributions to the literature include more than 225 research papers, editorials, monographs, book chapters and co-editorships.

Message Presenter
John W. Kennedy, AMGA

John W. Kennedy, MD, President, AMGA Foundation, Chief Medical Officer, AMGA

Dr. John Kennedy previously served as division director of endocrinology at Geisinger Health System in Danville, PA, where he led the clinical, education, research and quality program development and expansion for the health system.

Prior to his role at Geisinger, Dr. Kennedy served as managing partner at Diabetes & Endocrinology Associates, P.A., in Hamilton, NJ. There, he transitioned the hospital-owned group into a four-physician specialty private practice.

Dr. Kennedy is board certified in endocrinology, diabetes and metabolism. He received his Doctor of Medicine degree from Jefferson Medical College, now the Sidney Kimmel Medical College, in Philadelphia, PA. He performed his internal medicine residency at Thomas Jefferson University Hospital in Philadelphia, PA, and his fellowship in diabetes, endocrinology and metabolism at the Joslin Diabetes Center and Beth Israel Deaconess Medical Center in Boston, MA. Dr. Kennedy graduated Phi Beta Kappa from Dartmouth College in Hanover, NH, where he received his Bachelor of Arts degree in chemistry.

Message Presenter

Who Should Attend?

  • Chief Medical Officer
  • Chief Executive Officer
  • Senior Medical Director
  • Medical Director
  • Clinical Development Director
  • Research and Development Director
  • Operational Director
  • Senior Operational Director
  • Clinical Director
  • Senior Clinical Director
  • Research Director

What You Will Learn

After this webinar, participants will:

  • Gain insights into the depth and breadth of the Labcorp database and its potential uses
  • Understand how real-world data can support and improve clinical guideline development and adherence
  • Appreciate how large clinical datasets can improve efficiency of patient enrollment in metabolic disease research
  • Recognize how partnerships within healthcare can increase adoption of standards of care and drive medical innovation

Xtalks Partner

Labcorp Drug Development

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at or follow us on LinkedIn and Twitter @Labcorp.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account